Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijcard.2020.09.064 http://scihub22266oqcxt.onion/10.1016/j.ijcard.2020.09.064 33002521!7521414!33002521     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33002521&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Int+J+Cardiol 2021 ; 324 (?): 261-266 Nephropedia Template TP {{tp|p=33002521|t=2021. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence |pdf=|usr=}}{{33002521}} gab.com Text Antithrombotic therapy in patients with COVID-19 -Rationale and Evidence JO: Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33002521 #FOAvip In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exist. Preliminary observations on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy and in those requiring mechanical ventilation. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 outlines possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for this viral illness. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. We provide a practical approach on antithrombotic therapy management for COVID-19 patients from a multidisciplinary point of view. Twit Text FOAVip Antithrombotic therapy in patients with COVID-19 -Rationale and Evidence ????Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33002521 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33002521 #FOAvip English Wikipedia <ref>{{Cite pmid|33002521}}</ref> Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence #MMPMID33002521 Godino C; Scotti A; Maugeri N; Mancini N; Fominskiy E; Margonato A; Landoni G Int J Cardiol 2021[Feb]; 324 (?): 261-266 PMID33002521show ga In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exist. Preliminary observations on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy and in those requiring mechanical ventilation. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 outlines possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for this viral illness. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. We provide a practical approach on antithrombotic therapy management for COVID-19 patients from a multidisciplinary point of view. |*COVID-19 Drug Treatment[MESH] |Anticoagulants/therapeutic use[MESH] |COVID-19/*blood/physiopathology[MESH] |Evidence-Based Medicine/*trends[MESH] |Fibrinolytic Agents/*therapeutic use[MESH] |Humans[MESH]Antithrombotic therapy in patients with COVID-19? -Rationale and Evide(epmc).pdf DeepDyve Pubget Overpricing